Venetoclax 98% Purity BCL-2 Inhibitor CAS 1257044-40-8 Anticancer Small Molecule Compound Research Grade

Product Overview

Venetoclax is a first-in-class, orally bioavailable B-cell lymphoma 2 (BCL-2) inhibitor used for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). Marketed under the brand name Venclexta (Venclyxto in Europe), venetoclax was the first BCL-2 inhibitor approved by the FDA in April 2016, representing a breakthrough in targeted therapy for hematological malignancies. By selectively inhibiting the anti-apoptotic BCL-2 protein, venetoclax restores the apoptotic pathway in cancer cells, leading to programmed cell death.

Chemically, venetoclax is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide with the molecular formula C₄₅H₅₀ClN₇O₇S and a molecular weight of 868.44 g/mol. It is a pale yellow to yellow crystalline powder with solubility in DMSO and DMF. The compound exhibits high selectivity for BCL-2 over other BCL-2 family members and favorable pharmacokinetic properties.

Mechanism of Action

Venetoclax exerts its anticancer effects through targeted apoptosis induction:

• BCL-2 Inhibition: Potently and selectively binds to BCL-2, an anti-apoptotic protein overexpressed in many hematological malignancies

• Apoptosis Restoration: Displaces pro-apoptotic proteins (BIM, BAX, BAK) from BCL-2, restoring the intrinsic apoptotic pathway

• BH3 Mimetic: Acts as a BH3 mimetic, mimicking the activity of pro-apoptotic BH3-only proteins

• Tumor Cell Selectivity: Preferentially induces apoptosis in tumor cells with BCL-2 dependency, sparing normal cells

• Synergy with Other Agents: Enhances efficacy when combined with hypomethylating agents, rituximab, or other targeted therapies

Research Applications & Market Significance

Venetoclax has transformed the treatment landscape for hematological malignancies:

• Chronic Lymphocytic Leukemia (CLL): First-line and relapsed/refractory CLL treatment, including high-risk cytogenetic subgroups

• Small Lymphocytic Lymphoma (SLL): Approved for SLL with or without 17p deletion

• Acute Myeloid Leukemia (AML): First-line treatment for newly diagnosed AML in elderly or unfit patients, in combination with hypomethylating agents

• Other Hematological Malignancies: Research in multiple myeloma, mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma

• Solid Tumors: Emerging research in BCL-2-dependent solid tumors

• Combination Therapies: Extensive clinical development combining with immunotherapies, targeted agents, and chemotherapy

The global BCL-2 inhibitor market is expected to exceed $10 billion by 2028, driven by expanding indications and growing adoption in hematological malignancies. Venetoclax continues to lead the class with the broadest indication portfolio and strong clinical data.

Quality Specifications

Our venetoclax is manufactured under strict quality control conditions:

• Purity: ≥98.0% determined by HPLC

• Identity confirmed by NMR, mass spectrometry, and elemental analysis

• Water content: ≤0.5%

• Residual solvents: Meet ICH Q3C guidelines

• Heavy metals: ≤10 ppm

• Related substances: Each impurity ≤0.5%, total impurities ≤2.0%

• Each batch accompanied by comprehensive Certificate of Analysis (COA)

• Stable for 24 months when stored at -20°C in sealed containers protected from light

Packaging & Shipping

We offer flexible packaging options to meet diverse customer needs:

• Research quantities: 10mg, 50mg, 100mg, 500mg amber glass vials

• Bulk quantities: 1g, 5g, 10g amber glass bottles

• Custom packaging available upon request

• Shipped with cold packs for temperature-sensitive orders

• Cold chain shipping available upon request

• International shipping with proper documentation including MSDS and COA